<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320722</url>
  </required_header>
  <id_info>
    <org_study_id>2010-P-002049</org_study_id>
    <secondary_id>1R01HL105440</secondary_id>
    <nct_id>NCT01320722</nct_id>
  </id_info>
  <brief_title>Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function</brief_title>
  <acronym>MODERATE</acronym>
  <official_title>Modifiable Effectors of Renin System Activation: Treatment Evaluation (MODERATE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that, among non-hypertensive overweight and obese individuals,
      treatment of vitamin D deficiency and lowering uric acid concentrations (by either xanthine
      oxidase inhibition or increased renal excretion) will attenuate renin angiotensin system
      (RAS) activation, improve endothelial function, and lower blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have demonstrated that lower levels of 25-hydroxyvitamin D (25[OH]D) and higher
      concentrations of uric acid are both potentially modifiable factors that are independently
      associated with an increased risk of developing hypertension (high blood pressure) in humans.
      Other investigators have shown that vitamin D supplementation, or lowering uric acid with
      allopurinol, may reduce blood pressure. Animal experiments suggest that activation of both
      the systemic and local kidney-specific renin angiotensin systems (RAS) may be the principal
      mechanism linking 25(OH)D and uric acid with hypertension. In human parallels to these animal
      studies, we have shown in cross-sectional analyses that non-hypertensive individuals with
      lower 25(OH)D and higher uric acid levels have increased activation of their systemic and
      kidney-specific RAS, independent of other factors. However, whether vitamin D supplementation
      or uric acid lowering attenuates RAS activation has never been demonstrated in humans. Both
      lower 25(OH)D and higher uric acid concentrations are also associated with endothelial
      dysfunction in humans, and endothelial function may modulate the RAS and provide an alternate
      mechanism for the development of hypertension. It remains unclear, however, whether an
      intervention to increase 25(OH)D or decrease uric acid levels among non-hypertensive adults
      improves endothelial function; furthermore, it is unknown whether treatment of these
      individuals would lower blood pressure. Determining whether treatment of 25(OH)D and uric
      acid concentrations, per se, can attenuate RAS activation, improve endothelial function, and
      lower blood pressure among nonhypertensive individuals is critically important, with
      implications stretching beyond hypertension prevention, since RAS activation, endothelial
      dysfunction, and blood pressure are also implicated in the pathology of cardiovascular and
      chronic kidney disease. Individuals who are overweight and obese (two-thirds of US adults)
      represent an important population who are known to have lower 25(OH)D levels, higher uric
      acid concentrations, activation of the RAS, endothelial dysfunction, and an increased risk of
      hypertension, cardiovascular disease, and chronic kidney disease. Interestingly, our
      preliminary data demonstrate that among overweight and obese individuals with normal 25(OH)D
      or low uric acid levels, adiposity is no longer associated with activation of the RAS,
      suggesting that low 25(OH)D and high uric acid concentrations might be mediators of the
      adverse consequences of overweight and obesity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Renal Plasma Flow (RPF) in Response to Captopril in High Sodium Balance [Vitamin D]</measure>
    <time_frame>Week 8 (pre and post captopril)</time_frame>
    <description>Change in RPF in response to captopril is a measure of the vasodilator effect from inhibiting angiotensin II (AngII)- mediated vascular tone and therefore the degree of kidney specific Renin Angiotensin System (RAS) activity. Participants consumed a high sodium diet 3 days prior to the test. Following an 8 hour fast, participants remained in a supine (lying down) position and had an intravenous (IV) catheter inserted in each arm, one for infusion and one for blood collection. An 8 milligrams (mg)/kilogram(kg) loading dose of para-aminohippuric acid (PAH) was given, immediately followed by a continuous PAH infusion at 12 mg/minute. After 60 minutes a single dose of 25 mg of captopril was administered. Three pre-captopril measurements and three post-captopril measurements of RPF were made. RPF was normalized to body surface area of 1.73 meters squared (m^2). The change in RPF was calculated as post-captopril RPF- pre-captopril RPF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Renin Activity (PRA) [Vitamin D]</measure>
    <time_frame>Week 8</time_frame>
    <description>PRA is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma PRA was analyzed using a competitive binding radioimmunoassay (RIA) laboratory test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Angiotensin II (ATII) Concentration [Vitamin D]</measure>
    <time_frame>Week 8</time_frame>
    <description>ATII concentration is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma ATII was analyzed using a double-antibody radioimmunoassay (RIA) laboratory test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Renal Plasma Flow (RPF) Response to Captopril in High Sodium Balance [Uric Acid]</measure>
    <time_frame>Week 8 (pre and post captopril)</time_frame>
    <description>RPF in response to captopril iis a measure of the vasodilator effect from inhibiting angiotensin II (AngII)- mediated vascular tone and therefore the degree of kidney specific Renin Angiotensin System (RAS) activity. Participants consumed a high sodium diet 3 days prior to the test. Following an 8 hour fast, participants remained in a supine (lying down) position and had an intravenous (IV) catheter inserted in each arm, one for infusion and one for blood collection. An 8 milligrams (mg)/kilogram(kg) loading dose of para-aminohippuric acid (PAH) was given, immediately followed by a continuous PAH infusion at 12 mg/minute. After 60 minutes a single dose of 25 mg of captopril was administered. Three pre-captopril measurements and three post-captopril measurements of RPF were made. RPF was normalized to body surface area of 1.73 meters squared (m^2). The change in RPF was calculated as post-captopril RPF- pre-captopril RPF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Renin Activity (PRA) [Uric Acid]</measure>
    <time_frame>Week 8</time_frame>
    <description>PRA is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma PRA was analyzed using a competitive binding radioimmunoassay (RIA) laboratory test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Angiotensin II (ATII) Concentration [Uric Acid]</measure>
    <time_frame>Week 8</time_frame>
    <description>ATII concentration is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma ATII was analyzed using a double-antibody radioimmunoassay (RIA) laboratory test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Endothelium-Dependent Vasodilation (EDV)</measure>
    <time_frame>Baseline and Week 8 (pre and post ischaemic stimulus)</time_frame>
    <description>Endothelial function was assessed by EDV using brachial artery ultrasonography. Measurements of brachial artery diameter were made under basal conditions and reactive hyperemia following ischaemic stimulus. A blood pressure cuff on the forearm was pumped up for 5 minutes then released. Images were taken at baseline and after reactive hyperemia (increased blood flow). The maximum diameter was determined by the investigator. Change in EDV was expressed as a percent of brachial luminal diameter calculated as post-ischaemic brachial artery diameter - pre-ischaemic brachial artery diameter/pre-ischaemic brachial artery diameter * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 24-Hour Ambulatory Blood Pressure (ABP)</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>A 24-hour mean ambulatory blood pressure was monitored using a 24 hour ABP device. The ABP device is a small box that is worn on the belt or pant/skirt line with a line that connect under the clothing to the cuff on the upper arm. Blood Pressure was recorded every 30 minutes during the day and every 60 minutes during the night for 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 24-Hour Ambulatory Blood Pressure (ABP) Nocturnal Dipping</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>A 24-hour mean ambulatory blood pressure was monitored using a 24 hour ABP device. The ABP device is a small box that is worn on the belt or pant/skirt line with a line that connect under the clothing to the cuff on the upper arm. Blood Pressure was recorded every 30 minutes during the day and every 60 minutes during the night for 24 hours. Nocturnal dipping is the percent change lower between the daytime and nighttime values.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Renal Function</condition>
  <condition>Endothelial Function</condition>
  <condition>Blood Pressure</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probenecid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- Vitamin D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo soft gel once per week for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- Uric Acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D ergocalciferol</intervention_name>
    <description>50,000 unit soft gel capsule once per week for 8 weeks</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probenecid</intervention_name>
    <description>500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)</description>
    <arm_group_label>Probenecid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)</description>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo soft gel once per week for 8 weeks</description>
    <arm_group_label>Placebo- Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)</description>
    <arm_group_label>Placebo- Uric Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  25(OH)D &lt; 20 ng/mL OR Uric acid ≥ 5 mg/dL

          -  Age ≥ 18, ≤ 75 years

          -  Body Mass Index (BMI) ≥ 25 kg/m^2

        Exclusion Criteria:

          -  Hypertension, or on BP-lowering medicine

          -  Diabetes

          -  Coronary Heart Disease

          -  estimated glomerular filtration rate (EGFR) &lt;60 mL/min

          -  Kidney stones

          -  Active cancer (except non-melanoma skin cancer)

          -  Pregnant

          -  Taking vitamin D supplements and unwilling to stop

          -  Osteoporosis

          -  Hypo- or hypercalcemia

          -  Hypo- or hyperphosphatemia

          -  Known allergy to angiotensin-converting enzyme (ACE)-inhibitors

          -  Taking medication for hyperuricemia

          -  Gout, anemia, cirrhosis, active/chronic hepatitis, abnormal aspartate aminotransferase
             (AST), alanine aminotransferase (ALT) or total bilirubin levels, or anemia

          -  Known allergy to either allopurinol or probenecid

          -  Current use of didanosine, azothioprine, methotrexate, ketoprofen, ketorolac,
             mycophenolate, or ACE-inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Forman, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <results_first_submitted>March 13, 2017</results_first_submitted>
  <results_first_submitted_qc>May 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2017</results_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>John P. Forman</investigator_full_name>
    <investigator_title>INSTRUCTOR IN MEDICINE, BRIGHAM AND WOMEN'S HOSPITAL</investigator_title>
  </responsible_party>
  <keyword>renin angiotensin system</keyword>
  <keyword>vitamin D</keyword>
  <keyword>uric acid</keyword>
  <keyword>allopurinol</keyword>
  <keyword>probenecid</keyword>
  <keyword>endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Probenecid</mesh_term>
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D</title>
          <description>Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo- Vitamin D</title>
          <description>Placebo soft gel once per week for 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Probenecid</title>
          <description>Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).</description>
        </group>
        <group group_id="P4">
          <title>Allopurinol</title>
          <description>Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).</description>
        </group>
        <group group_id="P5">
          <title>Placebo- Uric Acid</title>
          <description>Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Intervention</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="48"/>
                <participants group_id="P5" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not Receive Intervention</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Available for the 8 Week Visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Developed a Rash</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant with Medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Compliant with Study Procedures</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Started an Exclusionary Medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew due to Health Condition</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D</title>
          <description>Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo- Vitamin D</title>
          <description>Placebo soft gel once per week for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Probenecid</title>
          <description>Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).</description>
        </group>
        <group group_id="B4">
          <title>Allopurinol</title>
          <description>Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).</description>
        </group>
        <group group_id="B5">
          <title>Placebo- Uric Acid</title>
          <description>Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="49"/>
            <count group_id="B5" value="53"/>
            <count group_id="B6" value="242"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>All randomized participants in the Vitamin D arms.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="13"/>
                    <measurement group_id="B2" value="35" spread="11"/>
                    <measurement group_id="B6" value="37" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>All randomized participants.</description>
          <population>All randomized participants in the Uric Acid arms.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="47"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="53"/>
                    <count group_id="B6" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="37" spread="14"/>
                    <measurement group_id="B4" value="43" spread="12.5"/>
                    <measurement group_id="B5" value="41" spread="14"/>
                    <measurement group_id="B6" value="41" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="47"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="53"/>
                    <count group_id="B6" value="242"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Change in Renal Plasma Flow (RPF) in Response to Captopril [Vitamin D]</title>
          <description>An 8 milligrams (mg)/kilogram(kg) loading dose of para-aminohippuric acid (PAH) was given, immediately followed by a continuous PAH infusion at 12 mg/minute. After 60 minutes a single dose of 25 mg of captopril was administered. Three pre-captopril measurements and three post-captopril measurements of RPF were made. RPF was normalized to body surface area of 1.73 meters squared (m^2). The change in RPF was calculated as post-captopril RPF- pre-captopril RPF.</description>
          <population>All randomized participants in the Vitamin D arms with data available for RPF.</population>
          <units>milliliters(mL)/minute(min) per 1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.9" spread="56.1"/>
                    <measurement group_id="B2" value="37.3" spread="46.9"/>
                    <measurement group_id="B6" value="35.6" spread="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Change in RPF in Response to Captopril [Uric Acid]</title>
          <description>An 8 milligrams (mg)/kilogram(kg) loading dose of para-aminohippuric acid (PAH) was given, immediately followed by a continuous PAH infusion at 12 mg/minute. After 60 minutes a single dose of 25 mg of captopril was administered. Three pre-captopril measurements and three post-captopril measurements of RPF were made. RPF was normalized to body surface area of 1.73 meters squared (m^2). The change in RPF was calculated as post-captopril RPF- pre-captopril RPF.</description>
          <population>All randomized participants in the Uric Acid arms with data available for RPF.</population>
          <units>mL/min per 1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="45"/>
                    <count group_id="B5" value="53"/>
                    <count group_id="B6" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="38" spread="46.0"/>
                    <measurement group_id="B4" value="41" spread="32.2"/>
                    <measurement group_id="B5" value="30" spread="35.5"/>
                    <measurement group_id="B6" value="36.3" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Renin Activity (PRA) [Vitamin D]</title>
          <population>All randomized participants in the Vitamin D arms with data available for PRA.</population>
          <units>nanograms (ng)/mL per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.34" spread="0.37"/>
                    <measurement group_id="B2" value="0.42" spread="0.44"/>
                    <measurement group_id="B6" value="0.38" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Renin Activity (PRA) [Uric Acid]</title>
          <population>All randomized participants in the Uric Acid arms with data available for PRA.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="35"/>
                    <count group_id="B5" value="43"/>
                    <count group_id="B6" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0.3" spread="0.52"/>
                    <measurement group_id="B4" value="0.3" spread="0.33"/>
                    <measurement group_id="B5" value="0.2" spread="0.33"/>
                    <measurement group_id="B6" value="0.27" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiotensin II Concentration (ATII) [Vitamin D]</title>
          <population>All randomized participants in the Vitamin D arms with data available for ATII.</population>
          <units>picogram(pg)/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.9" spread="5.9"/>
                    <measurement group_id="B2" value="19.9" spread="4.5"/>
                    <measurement group_id="B6" value="19.9" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiotensin II Concentration (ATII) [Uric Acid]</title>
          <population>All randomized participants in the Uric Acid arms with data available for ATII.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="34"/>
                    <count group_id="B5" value="45"/>
                    <count group_id="B6" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="19.6" spread="5.0"/>
                    <measurement group_id="B4" value="18.9" spread="4.0"/>
                    <measurement group_id="B5" value="18.8" spread="4.8"/>
                    <measurement group_id="B6" value="19.1" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Renal Plasma Flow (RPF) in Response to Captopril in High Sodium Balance [Vitamin D]</title>
        <description>Change in RPF in response to captopril is a measure of the vasodilator effect from inhibiting angiotensin II (AngII)- mediated vascular tone and therefore the degree of kidney specific Renin Angiotensin System (RAS) activity. Participants consumed a high sodium diet 3 days prior to the test. Following an 8 hour fast, participants remained in a supine (lying down) position and had an intravenous (IV) catheter inserted in each arm, one for infusion and one for blood collection. An 8 milligrams (mg)/kilogram(kg) loading dose of para-aminohippuric acid (PAH) was given, immediately followed by a continuous PAH infusion at 12 mg/minute. After 60 minutes a single dose of 25 mg of captopril was administered. Three pre-captopril measurements and three post-captopril measurements of RPF were made. RPF was normalized to body surface area of 1.73 meters squared (m^2). The change in RPF was calculated as post-captopril RPF- pre-captopril RPF.</description>
        <time_frame>Week 8 (pre and post captopril)</time_frame>
        <population>All randomized enrolled participants included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo- Vitamin D</title>
            <description>Placebo soft gel once per week for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Plasma Flow (RPF) in Response to Captopril in High Sodium Balance [Vitamin D]</title>
          <description>Change in RPF in response to captopril is a measure of the vasodilator effect from inhibiting angiotensin II (AngII)- mediated vascular tone and therefore the degree of kidney specific Renin Angiotensin System (RAS) activity. Participants consumed a high sodium diet 3 days prior to the test. Following an 8 hour fast, participants remained in a supine (lying down) position and had an intravenous (IV) catheter inserted in each arm, one for infusion and one for blood collection. An 8 milligrams (mg)/kilogram(kg) loading dose of para-aminohippuric acid (PAH) was given, immediately followed by a continuous PAH infusion at 12 mg/minute. After 60 minutes a single dose of 25 mg of captopril was administered. Three pre-captopril measurements and three post-captopril measurements of RPF were made. RPF was normalized to body surface area of 1.73 meters squared (m^2). The change in RPF was calculated as post-captopril RPF- pre-captopril RPF.</description>
          <population>All randomized enrolled participants included in the analysis.</population>
          <units>mL/min per 1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" spread="47.7"/>
                    <measurement group_id="O2" value="35.9" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Renin Activity (PRA) [Vitamin D]</title>
        <description>PRA is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma PRA was analyzed using a competitive binding radioimmunoassay (RIA) laboratory test.</description>
        <time_frame>Week 8</time_frame>
        <population>All randomized enrolled participants included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo- Vitamin D</title>
            <description>Placebo soft gel once per week for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Renin Activity (PRA) [Vitamin D]</title>
          <description>PRA is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma PRA was analyzed using a competitive binding radioimmunoassay (RIA) laboratory test.</description>
          <population>All randomized enrolled participants included in the analysis.</population>
          <units>ng/mL per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.44"/>
                    <measurement group_id="O2" value="0.44" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.77</p_value>
            <p_value_desc>Statistical significance was set for P&gt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Angiotensin II (ATII) Concentration [Vitamin D]</title>
        <description>ATII concentration is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma ATII was analyzed using a double-antibody radioimmunoassay (RIA) laboratory test.</description>
        <time_frame>Week 8</time_frame>
        <population>All randomized enrolled participants included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo- Vitamin D</title>
            <description>Placebo soft gel once per week for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiotensin II (ATII) Concentration [Vitamin D]</title>
          <description>ATII concentration is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma ATII was analyzed using a double-antibody radioimmunoassay (RIA) laboratory test.</description>
          <population>All randomized enrolled participants included in the analysis.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="4.4"/>
                    <measurement group_id="O2" value="19.7" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.57</p_value>
            <p_value_desc>Statistical significance was set for P&gt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Renal Plasma Flow (RPF) Response to Captopril in High Sodium Balance [Uric Acid]</title>
        <description>RPF in response to captopril iis a measure of the vasodilator effect from inhibiting angiotensin II (AngII)- mediated vascular tone and therefore the degree of kidney specific Renin Angiotensin System (RAS) activity. Participants consumed a high sodium diet 3 days prior to the test. Following an 8 hour fast, participants remained in a supine (lying down) position and had an intravenous (IV) catheter inserted in each arm, one for infusion and one for blood collection. An 8 milligrams (mg)/kilogram(kg) loading dose of para-aminohippuric acid (PAH) was given, immediately followed by a continuous PAH infusion at 12 mg/minute. After 60 minutes a single dose of 25 mg of captopril was administered. Three pre-captopril measurements and three post-captopril measurements of RPF were made. RPF was normalized to body surface area of 1.73 meters squared (m^2). The change in RPF was calculated as post-captopril RPF- pre-captopril RPF.</description>
        <time_frame>Week 8 (pre and post captopril)</time_frame>
        <population>All randomized enrolled participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Probenecid</title>
            <description>Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).</description>
          </group>
          <group group_id="O3">
            <title>Placebo- Uric Acid</title>
            <description>Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Plasma Flow (RPF) Response to Captopril in High Sodium Balance [Uric Acid]</title>
          <description>RPF in response to captopril iis a measure of the vasodilator effect from inhibiting angiotensin II (AngII)- mediated vascular tone and therefore the degree of kidney specific Renin Angiotensin System (RAS) activity. Participants consumed a high sodium diet 3 days prior to the test. Following an 8 hour fast, participants remained in a supine (lying down) position and had an intravenous (IV) catheter inserted in each arm, one for infusion and one for blood collection. An 8 milligrams (mg)/kilogram(kg) loading dose of para-aminohippuric acid (PAH) was given, immediately followed by a continuous PAH infusion at 12 mg/minute. After 60 minutes a single dose of 25 mg of captopril was administered. Three pre-captopril measurements and three post-captopril measurements of RPF were made. RPF was normalized to body surface area of 1.73 meters squared (m^2). The change in RPF was calculated as post-captopril RPF- pre-captopril RPF.</description>
          <population>All randomized enrolled participants with data available for analysis.</population>
          <units>mL/min per 1.73 m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="12" upper_limit="72"/>
                    <measurement group_id="O2" value="36" lower_limit="17" upper_limit="55"/>
                    <measurement group_id="O3" value="30" lower_limit="-1" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Renin Activity (PRA) [Uric Acid]</title>
        <description>PRA is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma PRA was analyzed using a competitive binding radioimmunoassay (RIA) laboratory test.</description>
        <time_frame>Week 8</time_frame>
        <population>All randomized enrolled participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Probenecid</title>
            <description>Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).</description>
          </group>
          <group group_id="O3">
            <title>Placebo- Uric Acid</title>
            <description>Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Renin Activity (PRA) [Uric Acid]</title>
          <description>PRA is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma PRA was analyzed using a competitive binding radioimmunoassay (RIA) laboratory test.</description>
          <population>All randomized enrolled participants with data available for analysis.</population>
          <units>ng/mL per hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.2" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.2" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.2" lower_limit="0.1" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Angiotensin II (ATII) Concentration [Uric Acid]</title>
        <description>ATII concentration is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma ATII was analyzed using a double-antibody radioimmunoassay (RIA) laboratory test.</description>
        <time_frame>Week 8</time_frame>
        <population>All randomized enrolled participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Probenecid</title>
            <description>Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).</description>
          </group>
          <group group_id="O3">
            <title>Placebo- Uric Acid</title>
            <description>Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).</description>
          </group>
        </group_list>
        <measure>
          <title>Angiotensin II (ATII) Concentration [Uric Acid]</title>
          <description>ATII concentration is a measure of systemic renin angiotensin system (RAS) activation. Blood was collected and plasma ATII was analyzed using a double-antibody radioimmunoassay (RIA) laboratory test.</description>
          <population>All randomized enrolled participants with data available for analysis.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="18.5" upper_limit="22.7"/>
                    <measurement group_id="O2" value="21.4" lower_limit="18.2" upper_limit="24.4"/>
                    <measurement group_id="O3" value="19.1" lower_limit="17.0" upper_limit="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Endothelium-Dependent Vasodilation (EDV)</title>
        <description>Endothelial function was assessed by EDV using brachial artery ultrasonography. Measurements of brachial artery diameter were made under basal conditions and reactive hyperemia following ischaemic stimulus. A blood pressure cuff on the forearm was pumped up for 5 minutes then released. Images were taken at baseline and after reactive hyperemia (increased blood flow). The maximum diameter was determined by the investigator. Change in EDV was expressed as a percent of brachial luminal diameter calculated as post-ischaemic brachial artery diameter - pre-ischaemic brachial artery diameter/pre-ischaemic brachial artery diameter * 100.</description>
        <time_frame>Baseline and Week 8 (pre and post ischaemic stimulus)</time_frame>
        <population>All randomized enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo- Vitamin D</title>
            <description>Placebo soft gel once per week for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Probenecid</title>
            <description>Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).</description>
          </group>
          <group group_id="O4">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).</description>
          </group>
          <group group_id="O5">
            <title>Placebo- Uric Acid</title>
            <description>Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Endothelium-Dependent Vasodilation (EDV)</title>
          <description>Endothelial function was assessed by EDV using brachial artery ultrasonography. Measurements of brachial artery diameter were made under basal conditions and reactive hyperemia following ischaemic stimulus. A blood pressure cuff on the forearm was pumped up for 5 minutes then released. Images were taken at baseline and after reactive hyperemia (increased blood flow). The maximum diameter was determined by the investigator. Change in EDV was expressed as a percent of brachial luminal diameter calculated as post-ischaemic brachial artery diameter - pre-ischaemic brachial artery diameter/pre-ischaemic brachial artery diameter * 100.</description>
          <population>All randomized enrolled participants.</population>
          <units>percent of brachial luminal diameter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="3.6"/>
                    <measurement group_id="O2" value="7.9" spread="4.7"/>
                    <measurement group_id="O3" value="7.4" spread="5.1"/>
                    <measurement group_id="O4" value="7.6" spread="6.0"/>
                    <measurement group_id="O5" value="6.5" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="4.6"/>
                    <measurement group_id="O2" value="6.8" spread="4.7"/>
                    <measurement group_id="O3" value="8.3" spread="5.1"/>
                    <measurement group_id="O4" value="6.2" spread="4.8"/>
                    <measurement group_id="O5" value="7.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Statistical significance was set for a 2-tailed P &lt;0.05.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7</p_value>
            <p_value_desc>Statistical significance was set for a 2-tailed P &lt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>Statistical significance was set for a 2-tailed P &lt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean 24-Hour Ambulatory Blood Pressure (ABP)</title>
        <description>A 24-hour mean ambulatory blood pressure was monitored using a 24 hour ABP device. The ABP device is a small box that is worn on the belt or pant/skirt line with a line that connect under the clothing to the cuff on the upper arm. Blood Pressure was recorded every 30 minutes during the day and every 60 minutes during the night for 24 hours.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>All randomized enrolled participants with complete 24-hour ABP data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo- Vitamin D</title>
            <description>Placebo soft gel once per week for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Probenecid</title>
            <description>Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).</description>
          </group>
          <group group_id="O4">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).</description>
          </group>
          <group group_id="O5">
            <title>Placebo- Uric Acid</title>
            <description>Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean 24-Hour Ambulatory Blood Pressure (ABP)</title>
          <description>A 24-hour mean ambulatory blood pressure was monitored using a 24 hour ABP device. The ABP device is a small box that is worn on the belt or pant/skirt line with a line that connect under the clothing to the cuff on the upper arm. Blood Pressure was recorded every 30 minutes during the day and every 60 minutes during the night for 24 hours.</description>
          <population>All randomized enrolled participants with complete 24-hour ABP data available for analysis.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Systolic Blood Pressure (SBP), Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.4" spread="10.2"/>
                    <measurement group_id="O2" value="123.7" spread="7.6"/>
                    <measurement group_id="O3" value="126.9" spread="10.2"/>
                    <measurement group_id="O4" value="124.1" spread="8.8"/>
                    <measurement group_id="O5" value="122.4" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Diastolic Blood Pressure (DBP), Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" spread="6.4"/>
                    <measurement group_id="O2" value="73.7" spread="5.8"/>
                    <measurement group_id="O3" value="73.3" spread="7.8"/>
                    <measurement group_id="O4" value="72.1" spread="7.1"/>
                    <measurement group_id="O5" value="71.9" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Awake SBP, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.4" spread="10.9"/>
                    <measurement group_id="O2" value="126.4" spread="7.4"/>
                    <measurement group_id="O3" value="130.0" spread="9.2"/>
                    <measurement group_id="O4" value="126.7" spread="8.4"/>
                    <measurement group_id="O5" value="125.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asleep SBP, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.9" spread="11.0"/>
                    <measurement group_id="O2" value="116.5" spread="8.7"/>
                    <measurement group_id="O3" value="119.2" spread="12.4"/>
                    <measurement group_id="O4" value="117.1" spread="10.0"/>
                    <measurement group_id="O5" value="113.9" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall SBP, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.6" spread="8.3"/>
                    <measurement group_id="O2" value="124.7" spread="9.6"/>
                    <measurement group_id="O3" value="125.2" spread="9.1"/>
                    <measurement group_id="O4" value="123.7" spread="9.4"/>
                    <measurement group_id="O5" value="122.9" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall DBP, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" spread="5.6"/>
                    <measurement group_id="O2" value="74.7" spread="7.2"/>
                    <measurement group_id="O3" value="73.8" spread="6.9"/>
                    <measurement group_id="O4" value="72.0" spread="6.5"/>
                    <measurement group_id="O5" value="72.6" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Awake SBP, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.2" spread="9.1"/>
                    <measurement group_id="O2" value="127.6" spread="9.2"/>
                    <measurement group_id="O3" value="128.1" spread="9.3"/>
                    <measurement group_id="O4" value="125.1" spread="9.6"/>
                    <measurement group_id="O5" value="124.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asleep SBP, Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.7" spread="8.1"/>
                    <measurement group_id="O2" value="117.4" spread="11.4"/>
                    <measurement group_id="O3" value="116.2" spread="9.6"/>
                    <measurement group_id="O4" value="118.6" spread="11.7"/>
                    <measurement group_id="O5" value="116.2" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.92</p_value>
            <p_value_desc>Statistical significance was set for P&gt;0.05.</p_value_desc>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall DBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.64</p_value>
            <p_value_desc>Statistical significance was set for P&gt;0.05.</p_value_desc>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Awake SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.80</p_value>
            <p_value_desc>Statistical significance was set for P&gt;0.05.</p_value_desc>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Asleep SBP at Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>Statistical significance was set for P&gt;0.05.</p_value_desc>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Overall SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Overall DBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Repeated Measures Analysi</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Awake SBF</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Asleep SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Overall SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Awake SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Asleep SBP</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean 24-Hour Ambulatory Blood Pressure (ABP) Nocturnal Dipping</title>
        <description>A 24-hour mean ambulatory blood pressure was monitored using a 24 hour ABP device. The ABP device is a small box that is worn on the belt or pant/skirt line with a line that connect under the clothing to the cuff on the upper arm. Blood Pressure was recorded every 30 minutes during the day and every 60 minutes during the night for 24 hours. Nocturnal dipping is the percent change lower between the daytime and nighttime values.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>All randomized enrolled participants with complete 24-hour ABP data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo- Vitamin D</title>
            <description>Placebo soft gel once per week for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Probenecid</title>
            <description>Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).</description>
          </group>
          <group group_id="O4">
            <title>Allopurinol</title>
            <description>Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).</description>
          </group>
          <group group_id="O5">
            <title>Placebo- Uric Acid</title>
            <description>Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean 24-Hour Ambulatory Blood Pressure (ABP) Nocturnal Dipping</title>
          <description>A 24-hour mean ambulatory blood pressure was monitored using a 24 hour ABP device. The ABP device is a small box that is worn on the belt or pant/skirt line with a line that connect under the clothing to the cuff on the upper arm. Blood Pressure was recorded every 30 minutes during the day and every 60 minutes during the night for 24 hours. Nocturnal dipping is the percent change lower between the daytime and nighttime values.</description>
          <population>All randomized enrolled participants with complete 24-hour ABP data available for analysis.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="6.3"/>
                    <measurement group_id="O2" value="7.8" spread="5.1"/>
                    <measurement group_id="O3" value="8.4" spread="6.8"/>
                    <measurement group_id="O4" value="7.5" spread="5.3"/>
                    <measurement group_id="O5" value="9.4" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="5.7"/>
                    <measurement group_id="O2" value="8.1" spread="6.0"/>
                    <measurement group_id="O3" value="9.2" spread="6.1"/>
                    <measurement group_id="O4" value="5.2" spread="7.1"/>
                    <measurement group_id="O5" value="6.9" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Repeated Measures Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All randomized participants who received study intervention.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D</title>
          <description>Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo- Vitamin D</title>
          <description>Placebo soft gel once per week for 8 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Probenecid</title>
          <description>Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).</description>
        </group>
        <group group_id="E4">
          <title>Allopurinol</title>
          <description>Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).</description>
        </group>
        <group group_id="E5">
          <title>Placebo- Uric Acid</title>
          <description>Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Decreased hematocrit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tingling in extremities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Altered taste</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Transient shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Transient nose bleed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Transient facial swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Unusual reaction to bee sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated phosphorus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Elevated potassium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Difficulty sleeping</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sensitivity to touch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John P Forman, MD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <email>jforman@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

